AbCellera Biologics (ABCL) vs Indivior Pharmaceuticals (INDV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AbCellera Biologics (ABCL) has outperformed Indivior Pharmaceuticals (INDV) over the past year, gaining 122.4% versus a gain of 52.3%. Over five years, INDV leads with a +127.9% price change compared with -17.4% for ABCL. Indivior Pharmaceuticals is the larger company by market cap ($4.26 billion vs $4.16 billion), about 1.0 times the size, while AbCellera Biologics is growing revenue faster (+160.6% vs +4.3%).
Indivior Pharmaceuticals converts more of its revenue into profit, with a net margin of 16.9% versus -194.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABCL | INDV |
|---|---|---|
| Share price | $12.83 | $36.13 |
| Market cap | $4.16B | $4.26B |
| 1-day change | -2.43% | +0.64% |
| YTD return | +275.15% | +0.70% |
| 1-year return | +122.36% | +52.32% |
| 5-year return | -17.39% | +127.95% |
| P/E ratio (TTM) | — | 12.95 |
| Forward P/E | — | 7.40 |
| EPS (TTM) | $-0.54 | $2.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $75.13M | $1.24B |
| Revenue growth (YoY) | +160.56% | +4.29% |
| Net income (latest FY) | $-146.41M | $210.00M |
| Gross margin | — | 80.23% |
| Operating margin | -288.98% | 21.15% |
| Net margin | -194.88% | 16.95% |
| 52-week high | $15.02 | $42.81 |
| 52-week low | $2.75 | $22.95 |
| Distance from 52-week high | -14.55% | -15.60% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +30.16% | +35.62% |
| Average volume | 6.74M | 2.07M |
| Shares outstanding | 324.05M | 118.03M |
| Employees | 562 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABCL has outperformed INDV by 70.0 percentage points over the past year.
- Indivior Pharmaceuticals is more profitable, keeping 16.9 cents of every revenue dollar as net income versus -194.9 cents for AbCellera Biologics.
- AbCellera Biologics grew revenue faster in its latest fiscal year (+160.56% vs +4.29%).
About AbCellera Biologics
ABCL stock →AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 562 employees
About Indivior Pharmaceuticals
INDV stock →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
ABCL vs INDV FAQ
Which is bigger, AbCellera Biologics or Indivior Pharmaceuticals?
Indivior Pharmaceuticals (INDV) is larger, with a market capitalization of $4.26B compared with $4.16B for AbCellera Biologics (ABCL).
Which stock has performed better over the past year, ABCL or INDV?
ABCL returned +122.36% over the past 12 months, compared with +52.32% for INDV (price return, excluding dividends). Past performance does not predict future results.
Are AbCellera Biologics and Indivior Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.